Jackpot 100
liked
$Ondas Holdings (ONDS.US)$ haha, you all know why it falling? coz i bought alot… as long as i keep the stock then it wont up for sure!
2
9
3
Jackpot 100
liked and commented on
Translated
1
31
ID: laylachi or Name: Roaming. Please search for me.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Moreover, Brother Huozhong's creed should be to focus on long-term investments. Recently, I made a short-term trade on IBRX and ended up with huge losses—I sold at $2.88 and bought back at $4, turning my cost from $2.13 into $3.14… Now I’m still crying in the bathroom $ImmunityBio (IBRX.US)$ The leading force in cancer innovation is making real progress. Dr. Patrick Soon-Shiong and ImmunityBio are advancing Anktiva, a groundbreaking IL-15 superagonist immunotherapy that activates and proliferates the body's natural killer (NK) cells and memory T cells to precisely target and destroy tumors.
Instead of using harsh chemotherapy that harms healthy cells and weakens immunity, Anktiva restores and strengthens the immune system for targeted, longer-lasting attacks, offering hope for fewer side effects and better outcomes.
The visionary behind it, @DrPatrick, a surgeon, inventor, and the founder, executive chairman, and global chief scientific officer of ImmunityBio.
Anktiva received FDA approval in 2024 for BCG-unresponsive non-muscle invasive #bladder cancer (NMIBC) with carcinoma in situ. In January 2026, the Saudi FDA granted accelerated approval for:
• Anktiva + checkpoint inhibitor in metastatic non-small cell #lungcancer (the world's first subcutaneous IL-15 treatment!)
• #Anktiva + BCG in BCG
unresponsive NMIBC
In addition, strong trial data shows immune restoration and extended survival times in difficult cases...
Instead of using harsh chemotherapy that harms healthy cells and weakens immunity, Anktiva restores and strengthens the immune system for targeted, longer-lasting attacks, offering hope for fewer side effects and better outcomes.
The visionary behind it, @DrPatrick, a surgeon, inventor, and the founder, executive chairman, and global chief scientific officer of ImmunityBio.
Anktiva received FDA approval in 2024 for BCG-unresponsive non-muscle invasive #bladder cancer (NMIBC) with carcinoma in situ. In January 2026, the Saudi FDA granted accelerated approval for:
• Anktiva + checkpoint inhibitor in metastatic non-small cell #lungcancer (the world's first subcutaneous IL-15 treatment!)
• #Anktiva + BCG in BCG
unresponsive NMIBC
In addition, strong trial data shows immune restoration and extended survival times in difficult cases...
Translated
2
Jackpot 100
commented on
$ImmunityBio (IBRX.US)$ gap 3ish from Jan 2025 filled. We need to break 8 to see over 10ish. On friday 7.5c 04/17/25 1.06, Buyers bought over 220k Call. I can feel over 10💰🙏
2
1
Jackpot 100
commented on
Jackpot 100
liked
$AMC Entertainment (AMC.US)$ as long as Apes still buy calls not shares the price wont go up. Gamma squeeze only occurs when there are lots of puts. not calls calls can cause reverse gamma squeeze. plus. options are unlimited but share of stocks are limited.
7
1
1
$ImmunityBio (IBRX.US)$ This passage comes from Dr. Patrick Soon-Shiong, the founder and executive chairman of ImmunityBio (stock code: IBRX). He is describing the company's latest 'Global Strategic Blueprint,' which focuses on leveraging the body's own immune system to revolutionize cancer treatment.
Below is a detailed interpretation of the 'blueprint' he mentioned.
1. Core Vision: Cancer BioShield™
This is a grand concept proposed by Dr. Huang. He believes that cancer treatment should not only focus on 'killing tumors' but also emphasize 'protecting the immune system.'
* Combating Lymphopenia: Traditional chemotherapy and radiotherapy destroy cancer cells while also wiping out immune cells (lymphocytes). Dr. Huang refers to this as 'immune system collapse.'
* Repair and Activation: The goal of the Cancer BioShield platform is to restore and enhance the patient’s immunity through its core drug Anktiva, acting like a 'shield' so that the body can continuously monitor and eliminate cancer cells, preventing recurrence.
2. Key Technologies and Drugs
* Anktiva (N-803): This is currently the company's flagship product. It is an IL-15 superagonist capable of potently activating natural killer cells (NK) and T cells...
Below is a detailed interpretation of the 'blueprint' he mentioned.
1. Core Vision: Cancer BioShield™
This is a grand concept proposed by Dr. Huang. He believes that cancer treatment should not only focus on 'killing tumors' but also emphasize 'protecting the immune system.'
* Combating Lymphopenia: Traditional chemotherapy and radiotherapy destroy cancer cells while also wiping out immune cells (lymphocytes). Dr. Huang refers to this as 'immune system collapse.'
* Repair and Activation: The goal of the Cancer BioShield platform is to restore and enhance the patient’s immunity through its core drug Anktiva, acting like a 'shield' so that the body can continuously monitor and eliminate cancer cells, preventing recurrence.
2. Key Technologies and Drugs
* Anktiva (N-803): This is currently the company's flagship product. It is an IL-15 superagonist capable of potently activating natural killer cells (NK) and T cells...
Translated
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)